Job Description
The Business Operations Partner supporting Research is responsible for the business operations activities: budget, resource management, and operational excellence within several Research Units. This role elevates strategic budget and resource management for the sub functions to ensure proactive resourcing decisions can be made. This role is focused on operationalizing financial and resourcing initiatives within Research and coordinating with the other business operations partners on such things as procedural guidance, strategic change, operational issues, budgeting and finance. This role is accountable for the cost centers business operations view for several Research Units.
Specific responsibilities include:
Partner with Research Units Leadership Teams
* Liaise with Leadership Teams to align current status and trajectory of budget and resources
* Facilitate resourcing/budget discussions on near term and long-term priorities
* Partner with RU LTs to define and monitor capacity and identify emerging issues
* Facilitate trade-off discussions and provide options to address emerging issues
* Conduit into R&D Strategy, Planning, Operations, and Communications for the function
* Support effective decision-making, based on a deep awareness of issues from an integrative, leadership perspective
* Serve as a member of the leadership teams, participate in/contribute to meetings and oversee tracking outcomes and deliverables
Cost Center Manager
* Responsible for business planning and analysis strategies. Implements and manages/oversees regular reporting and analytical cycle for the functions (such as AOP, resource allocation, and reports)
* Implement and maintain core management reporting, dashboards and key risk & performance indicators
* Ensure budgets and schedules meet organization requirements and standards and are in line with overall functional budget and projects.
Strategic Partner with Business Strategist, EAs, Finance, and Portfolio Directors
* Partner on resource planning and prioritization/trade-off initiatives
Optimization / Initiatives Driver
* Responsible for leading key efforts to improve business practices and processes to maximize resources and achieve operational excellence
* Proactively identify and oversee implementation of strategic process improvement efforts and remove roadblocks
* Coordinate with other business operations roles to enable alignment to overall resourcing goals and reporting templates and processes
Qualifications
* 5-8 years experience in Biotech and/or Pharmaceutical industry
* Experience (minimum 5 years) in business operations, budget management, process improvement, or other finance-related roles.
* Ability to work within matrix and influence without authority through formal channels and informal network
* Ability to work with agility, taking multi-faceted approaches to transfer knowledge and know-how, and form teams for follow-through
* Financial acumen, with an ability to evaluate budgets accounting, business case development
* Outstanding collaboration, communication and people skills
* Excellent organizational and analytical skills, detail oriented
Education:
* Bachelors degree. Advanced degree (MBA) preferred.
Additional Information
All your information will be kept confidential according to EEO guidelines.
Cambridge, MA
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies.
Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development.
The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.